Hans Jacobs and Pieter Langerhorst, theme Cancer development and immune defense, worked together with an international team of researchers, led by the Radboudumc and the Erasmus MC. They have developed a novel technique for the ultra-sensitive assessment of minimal residual disease (MRD) in a single drop of blood of patients with multiple myeloma using mass spectrometry.
In the latest edition of Clinical Chemistry they show that their blood-based method performs equally well compared to MRD-evaluation on bone marrow. “Through personalized diagnostics on one drop of blood, we can create a patient-friendly alternative to monitor minimal residual disease in myeloma patients,” says principle investigator Hans Jacobs, who is supported by a KWF grant.
Multiple Myeloma is the second most common hematological malignancy, characterized by cancer plasma cells in the bone marrow. These monoclonal plasma cells produce a patient and cancer specific monoclonal antibody (M-protein), which is used to monitor disease activity. There is not yet a cure for patients with multiple myeloma. However, due to improved treatment strategies an increased percentage of patients reach a state of MRD. In these patients disease load must be measured with invasive bone marrow aspirations because currently there is no method available that is sensitive enough to detect low disease activity in the blood.
The novel method is based on very sensitively measuring the unique patient-specific region of the M-protein by LC-MS/MS in a single drop of blood of patients with multiple myeloma (MS-MRD). In their publication in Clinical Chemistry the researchers showed that MS-MRD is 1000-fold more sensitive compared to current blood-based diagnostics. In a head-to-head comparison of MS-MRD with bone marrow-based MRD evaluation they found that the assays performed equally well to monitor MRD in patients with MM. The blood-based MS-MRD assay allows continuous MRD-evaluation over time “This opens the possibility to monitor these patients in greater detail, which is crucial for early detection of disease relapse” says PhD candidate Pieter Langerhorst (Dep. Laboratory Medicine). “We have created personalized diagnostics that can make a significant positive impact for myeloma patients. This study is a key step towards the implementation of our blood-based MS-MRD assay”.
Related news items
How much should we exercise to live healthier lives? Research into the relationship between exercise, heart disease and mortality3 December 2021
It has long been known that exercise reduces the risk of many chronic diseases. However, we do not yet know exactly how much exercise is necessary to achieve health benefit.read more
KNAW Early Career Award for Martine Hoogman2 December 2021
Martine Hoogman has been awarded a KNAW Early Career Award. The prize, a sum of 15,000 euros and a work of art, is aimed at researchers in the Netherlands who are at the start of their careers and have innovative, original research ideas.read more
T-Guard can reset immune system1 December 2021
For 20 years, the Nijmegen based Radboudumc spin-off company Xenikos has been working on a drug that can reset the immune system. This reset will save lives of seriously ill patients. Now, after years of hard work, the moment of truth has arrived for T-guard.read more
Thomas van den Heuvel wins Stairway to Impact Award for safer pregnancies using AI Award for safer pregnancies using AI1 December 2021
Radboudumc researcher Thomas van den Heuvel receives the Stairway to Impact Award from Dutch Research Council NWO. He receives this prize for the development of the BabyChecker, a smartphone application that allows midwives to make ultrasounds during pregnancies.read more
Villa Joep Research Grant for Radiotherapy & OncoImmunology (ROI) lab1 December 2021
Renske van den Bijgaart and Gosse Adema from the Radiotherapy & OncoImmunology laboratorium in collaboration with the Prinses Maxima Center received a grant from Villa Joep of 410k Euro.read more
Participating in cancer research among people with intellectual disabilities30 November 2021
Thanks to the support of the Maarten van der Weijden Foundation research was carried out into the participation of people with intellectual disabilities in (population) screening for cancer.read more